Drug intelligence / Profile preview

RGT-490

Development stage: Phase 1
Lead developer: Regor Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

RGT-490 is an investigational, orally bioavailable small molecule inhibitor developed by Regor Pharmaceuticals. It is designed to target the phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), a key component of the PI3K/AKT/mTOR signaling pathway that is frequently mutated in various malignancies. By inhibiting mutated PIK3CA, RGT-490 aims to suppress the aberrant signaling that drives tumor cell proliferation and survival. It is currently under clinical investigation in Phase 1/1b trials for patients with locally advanced or metastatic PIK3CA-mutated solid tumors, including hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer.

Targets

PIK3CA (Phosphoinositide 3-kinase alpha)

Beyond the preview

Go deeper on RGT-490.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGT-490.

Explore the full profile